Indikator likuiditas cepet anebulo.com (ANEB)

Anebulo Pharmaceuticals (ANEB) focuses on developing treatments for cannabis overdose, utilizing expert-supervised automated pill synthesis. The expansion of addiction therapy programs mitigates regulatory risks, while a narrow specialization in the final stages of antidote testing ensures efficacy. This price chart, where the indicator stands at 6.13, confirms the fundamental stability of this innovative biotech.

The quick ratio measures a business's ability to meet its immediate obligations, considering only cash and accounts receivable while completely excluding illiquid inventories. By analyzing the current quick ratio, an investor assesses the financial stability of Anebulo Pharmaceuticals (ANEB), which is critical in the narrow niche of cannabinoid antidotes, where a limited sales market increases the risk of payment delays from counterparties.